New Support for Old Medications in Resistant Hypertension

Robert D Brook¹, Jordana B Cohen^{2

3}, Sanjay Rajagopalan^{4

5}

Affiliations

¹ Division of Cardiovascular Diseases, Department of Internal Medicine, Wayne State University, Detroit, Michigan.
² Renal-Electrolyte and Hypertension Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
³ Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
⁴ University Hospitals, Harrington Heart and Vascular Institute, Cleveland, Ohio.
⁵ Case Western Reserve University School of Medicine, Cleveland, Ohio.

Comment

Robert D Brook et al. JAMA. 2025.

. 2025 Jun 17;333(23):2058-2060.

doi: 10.1001/jama.2025.4321.

Robert D Brook¹, Jordana B Cohen^{2

3}, Sanjay Rajagopalan^{4

5}

¹ Division of Cardiovascular Diseases, Department of Internal Medicine, Wayne State University, Detroit, Michigan.
² Renal-Electrolyte and Hypertension Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
³ Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
⁴ University Hospitals, Harrington Heart and Vascular Institute, Cleveland, Ohio.
⁵ Case Western Reserve University School of Medicine, Cleveland, Ohio.

No abstract available

Comment on

Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial.
Lee CJ, Ihm SH, Shin DH, Jeong JO, Kim JH, Chun KH, Ryu J, Lee HY, Choi S, Lee EM, Choi JH, Kim KI, Shin J, Pyun WB, Kim DH, Park S, Williams B. Lee CJ, et al. JAMA. 2025 Jun 17;333(23):2073-2082. doi: 10.1001/jama.2025.5129. JAMA. 2025. PMID: 40366680 Free PMC article. Clinical Trial.